Pure Global
NCT05140213

A STUDY BEFORE/AFTER THE IMPLEMENTATION OF AN ANTI-INFECTIOUS PRESCRIPTION AID

EVALUATION OF 30-DAY MORTALITY AFTER A VISIT TO THE LAPEYRONIE ADULT EMERGENCY DEPARTMENT OF THE CHU MONTPELLIER FOR SEPSIS OR SEPTIC SHOCK
University Hospital, Montpellier·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
Anti-infectious prescription support tool
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
University Hospital, Montpellier
Location
Montpellier, France
Timeline & enrollment
Phase
N/A
Start date
Dec 12, 2020
End date
Aug 30, 2021
Enrollment
371 participants
Primary outcome

Numbers of patient 30-day mortality

Summary

Anti-infective strategy is a major public health problem. This is a before-and-after study of
 an anti-infectious prescription tool with a comparison of mortality at 30 days (then 3 and 6
 months) between the two inclusion phases of 6 months each.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05140213
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05140213 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Montpellier and is currently Completed. The study focuses on Sepsis,Septic Shock. Target enrollment is 371 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.